-
-
-
-
-
-
-
Amarin Corp. (AMRN) Announces EMA to Validate Marketing Authotization Application for Icosapent Ethyl (Vascepa)
-
-
-
-
-
-
-
Cantor Fitzgerald Expects Shares of Amarin (AMRN) to Rise After 16-0 Favorable FDA Adcom Vote
-
-
-
-
-
-
-
Amarin Corporation (AMRN) Could Have 20% Upside Over the Next Week - Citi
-
-
-
-
-
-
-
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke a
-
-
-
-
-
-
-
Amarin Corp. (AMRN) Said FDA Confirms December 28 PDUFA Date for REDUCE-IT sNDA
-
-
-
-
-
-
-
Amarin Corp. (AMRN) Tops Q2 EPS by 4c, Revenues Beat
-
-
-
-
-
-
-
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance
-
12,339 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All